IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v2y2011i1d10.1038_ncomms1341.html
   My bibliography  Save this article

Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites

Author

Listed:
  • Darragh B. Freir

    (Laboratory for Neurodegenerative Research, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin)

  • Andrew J. Nicoll

    (UCL Institute of Neurology, Queen Square, London WCN1 3BG, UK.)

  • Igor Klyubin

    (Institute of Neuroscience, Biotechnology Building, Trinity College, Dublin 2, Republic of Ireland.)

  • Silvia Panico

    (Institute of Structural and Molecular Biology, Birkbeck College)

  • Jessica M. Mc Donald

    (Laboratory for Neurodegenerative Research, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin)

  • Emmanuel Risse

    (UCL Institute of Neurology, Queen Square, London WCN1 3BG, UK.)

  • Emmanuel A. Asante

    (UCL Institute of Neurology, Queen Square, London WCN1 3BG, UK.)

  • Mark A. Farrow

    (UCL Institute of Neurology, Queen Square, London WCN1 3BG, UK.)

  • Richard B. Sessions

    (School of Medical Sciences, University of Bristol)

  • Helen R. Saibil

    (Institute of Structural and Molecular Biology, Birkbeck College)

  • Anthony R. Clarke

    (UCL Institute of Neurology, Queen Square, London WCN1 3BG, UK.
    School of Medical Sciences, University of Bristol)

  • Michael J. Rowan

    (Institute of Neuroscience, Biotechnology Building, Trinity College, Dublin 2, Republic of Ireland.)

  • Dominic M. Walsh

    (Laboratory for Neurodegenerative Research, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin)

  • John Collinge

    (UCL Institute of Neurology, Queen Square, London WCN1 3BG, UK.)

Abstract

A role for PrP in the toxic effect of oligomeric forms of Aβ, implicated in Alzheimer's disease (AD), has been suggested but remains controversial. Here we show that PrP is required for the plasticity-impairing effects of ex vivo material from human AD brain and that standardized Aβ-derived diffusible ligand (ADDL) preparations disrupt hippocampal synaptic plasticity in a PrP-dependent manner. We screened a panel of anti-PrP antibodies for their ability to disrupt the ADDL–PrP interaction. Antibodies directed to the principal PrP/Aβ-binding site and to PrP helix-1, were able to block Aβ binding to PrP suggesting that the toxic Aβ species are of relatively high molecular mass and/or may bind multiple PrP molecules. Two representative and extensively characterized monoclonal antibodies directed to these regions, ICSM-35 and ICSM-18, were shown to block the Aβ-mediated disruption of synaptic plasticity validating these antibodies as candidate therapeutics for AD either individually or in combination.

Suggested Citation

  • Darragh B. Freir & Andrew J. Nicoll & Igor Klyubin & Silvia Panico & Jessica M. Mc Donald & Emmanuel Risse & Emmanuel A. Asante & Mark A. Farrow & Richard B. Sessions & Helen R. Saibil & Anthony R. Cl, 2011. "Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites," Nature Communications, Nature, vol. 2(1), pages 1-9, September.
    • Handle: RePEc:nat:natcom:v:2:y:2011:i:1:d:10.1038_ncomms1341
    DOI: 10.1038/ncomms1341
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms1341
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms1341?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:2:y:2011:i:1:d:10.1038_ncomms1341. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.